Analyst Consensus ?
ConsensusBuy52 ratings
Bullish3873.1%
Neutral1325.0%
Bearish11.9%
Alnylam Pharmaceuticals, Inc. · ALNY · FY2026 Q2 · Calendar Q3 2026
Alnylam grows AMVUTTRA while lowering 2026 revenue guidance
Alnylam's growth case is supported by AMVUTTRA's strong first-line adoption, a broad pipeline, and geographic and diagnostic expansion. The main counterweight is that normalized second-line demand prompted a $200 million guidance reduction, leaving execution, pricing, payer access, and clinical outcomes as key tests.
Reported Before market openNASDAQHealthcare
$22.08B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.21
Consensus $1.63
EPS surprise
-25.8%
Reported versus consensus
Reported revenue
$1.29B
Consensus $1.32B
Revenue surprise
-2.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-28.3%
Event window
SPY move
+1.7%
Same window
Abnormal move
-30.0%
Stock minus SPY
Volume
6.3×
Versus trailing sessions
Subsequent drift
+15.1%
Up to 20 sessions
ALNYSPY benchmark
Ask FN2 about ALNY FY2026 Q2
Transcript, numbers and history already loaded
Why did ALNY fall 28.3% after missing EPS estimates in FY2026 Q2?What changed in ALNY's guidance and outlook in FY2026 Q2?Give me the bull and bear case for ALNY after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
AMVUTTRA surpassed $1 billion in quarterly revenue and first-line starts reached about 80% of new patients. Against that progress, management lowered 2026 revenue guidance by $200 million because second-line demand normalized, while highlighting new AI collaborations, the BeOne China partnership, and additional pipeline activity.
Guidance delta
Management lowered 2026 revenue guidance by $200 million, citing normalized second-line demand, while retaining a 75% year-over-year growth trajectory.
Key takeaways
- AMVUTTRA exceeded $1 billion in quarterly revenue, with first-line starts representing about 80% of new patients.
- Management said the competitive backdrop improved, citing delayed generic tafamidis entry and eplontersen's failure.
- AI collaborations, prescriber expansion, and the BeOne partnership support diagnosis, access, and geographic growth.
- The pipeline remains central, with programs including nucresiran, ALN-6400, mivelsiran, and ALN-HTT02.
Management priorities
- Broaden AMVUTTRA adoption through commercial efforts and community-physician outreach.
- Advance AI-enabled diagnosis and evidence-generation initiatives.
- Prepare for the AMVUTTRA China launch and deliver multiple 2026 pipeline readouts.
Follow ALNY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$165Current
$96Low
$341.04Average
$570High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Oct 30, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 30, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 30, 2026 |
| Raymond James | Outperform | Strong Buy | Downgrade | Oct 30, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 30, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 30, 2026 |
| Bernstein | Market Perform | Outperform | Downgrade | Oct 30, 2026 |
| Needham | Buy | Buy | Maintain | Oct 29, 2026 |
| Citigroup | Buy | Buy | Maintain | Oct 14, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Sep 30, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Sep 21, 2026 |
| Jefferies | Hold | Hold | Maintain | Sep 8, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Aug 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 4, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 3, 2026 |
| Stifel | Buy | Buy | Maintain | Jul 31, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Jul 31, 2026 |
| Chardan Capital | Buy | Buy | Maintain | Jul 31, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 14, 2026 |
| Freedom Capital Markets | Buy | Hold | Upgrade | Feb 17, 2026 |
| Freedom Broker | Buy | Hold | Upgrade | Feb 17, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Feb 17, 2026 |
| Leerink Partners | Market Perform | Market Perform | Maintain | Dec 15, 2025 |
| Piper Sandler | Overweight | Overweight | Maintain | Oct 31, 2025 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Sep 11, 2025 |
| Wolfe Research | Peer Perform | Underperform | Upgrade | Aug 4, 2025 |
| UBS | Buy | Buy | Maintain | Aug 1, 2025 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Aug 1, 2025 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Oct 11, 2024 |
| SMBC Nikko | Neutral | Neutral | Maintain | Apr 26, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Jan 23, 2023 |
| Guggenheim | Neutral | Buy | Downgrade | Jun 27, 2022 |
| William Blair | Outperform | Outperform | Maintain | Jun 7, 2022 |
| Nomura | Reduce | Reduce | Maintain | Apr 14, 2020 |
| Berenberg | Buy | Buy | Maintain | Mar 19, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 13, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Sep 3, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Apr 15, 2019 |
| Leerink Swann | Perform | Market Perform | Maintain | Nov 28, 2018 |
| Cowen & Co. | Outperform | Outperform | Maintain | Aug 13, 2018 |
| B. Riley Securities | Buy | Buy | Maintain | Aug 13, 2018 |
| B. Riley FBR | Buy | Buy | Maintain | Aug 13, 2018 |
| Credit Suisse | Outperform | Outperform | Maintain | Mar 13, 2018 |
| B. Riley | Buy | Buy | Maintain | Nov 8, 2017 |
| FBR Capital | Buy | Buy | Maintain | Nov 2, 2017 |
| Ladenburg Thalmann | Buy | Buy | Maintain | Feb 2, 2017 |
| Janney Capital | Neutral | Neutral | Maintain | Sep 29, 2016 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Mar 9, 2016 |
| PiperJaffray | Outperform | Outperform | Maintain | Jun 15, 2015 |
| S&P Capital IQ | Buy | Hold | Upgrade | Jan 27, 2014 |
| Deutsche Bank | Buy | Buy | Maintain | Sep 24, 2013 |
| McNicoll Lewis Vlak | Hold | Buy | Downgrade | Feb 9, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $165. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Joon Lee | $329 | $169.42 | +99.4% | Oct 30, 2026 |
| BMO Capital | David Lebowitz | $290 | $174 | +75.8% | Oct 30, 2026 |
| Wells Fargo | Analyst unavailable | $287 | $174 | +73.9% | Oct 30, 2026 |
| Raymond James | Martin Auster | $315 | $174 | +90.9% | Oct 30, 2026 |
| Stifel Nicolaus | Paul Matteis | $225 | $177.48 | +36.4% | Oct 29, 2026 |
| UBS | Joon Lee | $354 | $224.47 | +114.5% | Oct 15, 2026 |
| Wells Fargo | Derek Archila | $253 | $223.82 | +53.3% | Oct 14, 2026 |
| RBC Capital | Luca Issi | $345 | $222.62 | +109.1% | Oct 8, 2026 |
| Jefferies | Analyst unavailable | $260 | $266.11 | +57.6% | Sep 8, 2026 |
| Jefferies | Analyst unavailable | $230 | $233.5 | +39.4% | Aug 28, 2026 |
| Bernstein | Jeffrey Walch | $376 | $236.01 | +127.9% | Aug 25, 2026 |
| BMO Capital | Analyst unavailable | $318 | $228.61 | +92.7% | Aug 18, 2026 |
| Wells Fargo | Derek Archila | $256 | $227.12 | +55.2% | Aug 14, 2026 |
| H.C. Wainwright | Analyst unavailable | $455 | $215.61 | +175.8% | Aug 4, 2026 |
| Truist Financial | Analyst unavailable | $315 | $220.33 | +90.9% | Aug 4, 2026 |
| Barclays | Eliana Merle | $450 | $205.52 | +172.7% | Aug 3, 2026 |
| Raymond James | Martin Auster | $420 | $203.31 | +154.5% | Jul 31, 2026 |
| RBC Capital | Luca Issi | $350 | $203.29 | +112.1% | Jul 31, 2026 |
| Oppenheimer | Analyst unavailable | $350 | $205.48 | +112.1% | Jul 31, 2026 |
| Morgan Stanley | Analyst unavailable | $300 | $205.48 | +81.8% | Jul 31, 2026 |
| Stifel Nicolaus | Paul Matteis | $318 | $205.48 | +92.7% | Jul 31, 2026 |
| H.C. Wainwright | Analyst unavailable | $485 | $288.08 | +193.9% | Jul 13, 2026 |
| Truist Financial | Analyst unavailable | $410 | $298.76 | +148.5% | Jul 13, 2026 |
| Morgan Stanley | Analyst unavailable | $400 | $307.42 | +142.4% | Jul 10, 2026 |
| Raymond James | Analyst unavailable | $468 | $322.64 | +183.6% | Jul 9, 2026 |
| H.C. Wainwright | Analyst unavailable | $470 | $291.37 | +184.8% | Jun 29, 2026 |
| Morgan Stanley | Analyst unavailable | $370 | $301.45 | +124.2% | May 1, 2026 |
| Bernstein | Analyst unavailable | $447 | $302.85 | +170.9% | May 1, 2026 |
| Canaccord Genuity | Analyst unavailable | $429 | $314.4 | +160.0% | Feb 17, 2026 |
| Morgan Stanley | Analyst unavailable | $360 | $313.75 | +118.2% | Feb 13, 2026 |
| Bernstein | Analyst unavailable | $451 | $312.43 | +173.3% | Feb 13, 2026 |
| Chardan Capital | Analyst unavailable | $425 | $308.48 | +157.6% | Feb 13, 2026 |
| Stifel Nicolaus | Paul Matteis | $444 | $313.05 | +169.1% | Feb 12, 2026 |
| H.C. Wainwright | Analyst unavailable | $510 | $346.79 | +209.1% | Jan 30, 2026 |
| RBC Capital | Analyst unavailable | $465 | $359 | +181.8% | Jan 20, 2026 |
| Wells Fargo | Analyst unavailable | $376 | $359 | +127.9% | Jan 20, 2026 |
| Needham | Analyst unavailable | $529 | $398.29 | +220.6% | Jan 12, 2026 |
| Raymond James | Martin Auster | $472 | $398.29 | +186.1% | Jan 12, 2026 |
| Truist Financial | Analyst unavailable | $530 | $419.08 | +221.2% | Jan 8, 2026 |
| Bernstein | Analyst unavailable | $491 | $387.44 | +197.6% | Jan 6, 2026 |
| Leerink Partners | Mani Foroohar | $351 | $399.42 | +112.7% | Dec 15, 2025 |
| Stifel Nicolaus | Analyst unavailable | $508 | $404.46 | +207.9% | Dec 11, 2025 |
| H.C. Wainwright | Patrick Trucchio | $570 | $434.07 | +245.5% | Nov 4, 2025 |
| Barclays | Analyst unavailable | $527 | $449.56 | +219.4% | Oct 31, 2025 |
| Oppenheimer | Leland Gershell | $500 | $449.56 | +203.0% | Oct 31, 2025 |
| Chardan Capital | Keay Nakae | $475 | $449.56 | +187.9% | Oct 31, 2025 |
| UBS | Analyst unavailable | $549 | $449.56 | +232.7% | Oct 30, 2025 |
| Morgan Stanley | Michael Ulz | $495 | $449.56 | +200.0% | Oct 30, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $450 | $474 | +172.7% | Oct 22, 2025 |
| Truist Financial | Analyst unavailable | $535 | $479.18 | +224.2% | Oct 17, 2025 |
| Morgan Stanley | Michael Ulz | $475 | $456.35 | +187.9% | Oct 6, 2025 |
| Stifel Nicolaus | Paul Matteis | $495 | $456.35 | +200.0% | Oct 6, 2025 |
| BMO Capital | Kostas Biliouris | $470 | $452.81 | +184.8% | Sep 5, 2025 |
| Raymond James | Analyst unavailable | $370 | $330.55 | +124.2% | Jul 29, 2025 |
| Truist Financial | Danielle Brill | $385 | $324.49 | +133.3% | Jul 21, 2025 |
| BMO Capital | Kostas Biliouris | $360 | $325 | +118.2% | Jun 24, 2025 |
| Scotiabank | Analyst unavailable | $338 | $283.34 | +104.8% | Mar 21, 2025 |
| Bernstein | William Pickering | $310 | $235.95 | +87.9% | Jan 7, 2025 |
| Canaccord Genuity | Whitney Ijem | $336 | $294.87 | +103.6% | Oct 24, 2024 |
| Canaccord Genuity | Whitney Ijem | $366 | $273.69 | +121.8% | Oct 1, 2024 |
| Bank of America Securities | Tazeen Ahmad | $307 | $274.91 | +86.1% | Sep 27, 2024 |
| BMO Capital | Kostas Biliouris | $300 | $269.31 | +81.8% | Aug 27, 2024 |
| RBC Capital | Luca Issi | $300 | $271.42 | +81.8% | Aug 26, 2024 |
| Goldman Sachs | Salveen Richter | $370 | $262.7 | +124.2% | Aug 16, 2024 |
| Canaccord Genuity | Whitney Ijem | $357 | $253.86 | +116.4% | Jul 8, 2024 |
| UBS | Esther Rajavelu | $288 | $247 | +74.5% | Jun 28, 2024 |
| RBC Capital | Luca Issi | $265 | $245.17 | +60.6% | Jun 27, 2024 |
| Stifel Nicolaus | Paul Matteis | $295 | $247.4 | +78.8% | Jun 27, 2024 |
| Evercore ISI | Liisa Bayko | $260 | $222.9 | +57.6% | Jun 25, 2024 |
| RBC Capital | Luca Issi | $250 | $222.9 | +51.5% | Jun 25, 2024 |
| Morgan Stanley | Andrew Galler | $250 | $224.7 | +51.5% | Jun 24, 2024 |
| H.C. Wainwright | Patrick Trucchio | $400 | $227.05 | +142.4% | Jun 24, 2024 |
| Stifel Nicolaus | Paul Matteis | $247 | $227.92 | +49.7% | Jun 24, 2024 |
| RBC Capital | Luca Issi | $235 | $156.43 | +42.4% | Jun 12, 2024 |
| BMO Capital | Kostas Biliouris | $234 | $156.59 | +41.8% | Apr 8, 2024 |
| Piper Sandler | Edward Tenthoff | $253 | $229.37 | +53.3% | Dec 15, 2022 |
| Cantor Fitzgerald | Olivia Brayer | $175 | $145.85 | +6.1% | Jul 12, 2022 |
| Piper Sandler | Edward Tenthoff | $208 | $135.82 | +26.1% | Jun 14, 2022 |
| H.C. Wainwright | Analyst unavailable | $430 | $133.43 | +160.6% | May 2, 2022 |
| BMO Capital | Analyst unavailable | $166 | $137.8 | +0.6% | Apr 29, 2022 |
| Citigroup | Analyst unavailable | $211 | $136.67 | +27.9% | Apr 29, 2022 |
| Leerink Partners | Analyst unavailable | $96 | $143.16 | -41.8% | Apr 29, 2022 |
| Morgan Stanley | Analyst unavailable | $178 | $167 | +7.9% | Apr 25, 2022 |
| Berenberg Bank | Zhiqiang Shu | $154 | $150.76 | -6.7% | Feb 11, 2022 |
| BMO Capital | Gary Nachman | $175 | $150.76 | +6.1% | Feb 11, 2022 |
| RBC Capital | Luca Issi | $225 | $150.86 | +36.4% | Feb 10, 2022 |
| Guggenheim | Debjit Chattopadhyay | $170 | $142.51 | +3.0% | Feb 3, 2022 |
| Bank of America Securities | Tazeen Ahmad | $209 | $130.12 | +26.7% | Jan 26, 2022 |
| Jefferies | Maury Raycroft | $205 | $136.53 | +24.2% | Jan 23, 2022 |
| Cowen & Co. | Ritu Baral | $250 | $186.42 | +51.5% | Dec 13, 2021 |
| Goldman Sachs | Salveen Richter | $273 | $187.01 | +65.5% | Nov 22, 2021 |
| Cantor Fitzgerald | Alethia Young | $275 | $159.56 | +66.7% | Oct 29, 2021 |
| UBS | Esther Rajavelu | $211 | $159.56 | +27.9% | Oct 29, 2021 |
| Evercore ISI | Maneka Mirchandaney | $190 | $159.56 | +15.2% | Oct 29, 2021 |
| Barclays | Gena Wang | $210 | $162.14 | +27.3% | Oct 28, 2021 |
Track every rating change on ALNY the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline.…
Historical context
All ALNY earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
Latest beats and misses
Who reports nextBeat on EPS
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
- ABBVFY2026 Q3 · October 30, 2026+2.4% EPS+1.4% move
- GDFY2026 Q3 · October 30, 2026+9.0% EPS+0.5% move
- MGAFY2026 Q3 · October 30, 2026+15.8% EPS-1.4% move
Missed on EPS
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
- AMZNFY2026 Q3 · October 29, 2026-4.1% EPS-1.6% move
Get the ALNY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-30T22:11:02.060115+00:00
- FN2 earnings calendar · 2026-09-04T01:23:15.205020+00:00
- Polygon adjusted daily market bars · 2026-10-31T12:00:45.655605+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-31T12:00:45.652728+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.